Google has signed a lease for a full floor in Buffalo Heights One, a mixed-use development anchored by H-E-B. Photo via buffaloheightsdistrict.com

Within the same week, two tech giants have announced plans to enter or expand in Houston. Amazon has began building out a robotic distribution center in Fort Bend County, and Google will open its first office in Houston focused on cloud technology sales.

Dallas-based real estate developer Trammell Crow Company has began construction on Amazon's ecommerce fulfillment center in Richmond, Texas, located on 93.5 acres at 10507 Harlem Road. The 850,000-square-foot facility will open in 2021.

"We're delighted to continue our growth and investment in Texas, with our new fulfillment center in Richmond," says Alicia Boler Davis, Amazon's vice president of global customer fulfillment, in a news release. "This new fulfillment center will create more than 1,000 new full-time jobs, in addition to the more than 20,000 current employees across the state, who receive industry-leading pay and benefits starting on day one."

According to the news release, the new fulfillment center will be equipped with Amazon robotics technology just like the company's North Houston distribution center.

Meanwhile, Google has signed a lease with BKR Memorial for an entire floor at One Buffalo Heights building (3663 Washington Ave.), which is anchored by H-E-B. The office won't have any technology-focused employees, rather will be a regional hub for Cloud Enterprise Sales. The location will deliver in early 2021.

"Google is a major player, not just as a driver of innovation and economic transformation, but also as an engaged member of the community," says Russell Gordy, CEO of BKR, in a news release. "We are pleased they chose Buffalo Heights when they were making a commitment to Houston."

Last year, Google invested in offices across the state, including two additional offices in Austin and a $600 million data center in Midlothian — which is 25 miles southwest of Dallas. Google first opened an office in Austin in 2007.

"Texas continues to be an innovation hub for the south," says Lauren Lambert, head of public policy and government relations in Texas, in the release. "The state's culture, diversity and strong emphasis on community makes it a perfect fit for Google and we look forward to calling Texas home for years to come."

Google's nonprofit arm recently donated $100,000 to go toward aiding families in Houston that were impacted by COVID-19. Over 100 families will receive $1,000 in direct cash payments.

"Houston is a hub for innovation and technology and the digital universe," says Mayor Sylvester Turner in the release. The new office "is crucial for the long-term health and resiliency of our city. The goal is to grow top-paying jobs for residents and new arrivals. Companies like Google see what we already know about our city: the greatest and most creative minds live and work in Houston."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”